pharma · SBRT · Covid19 · GRTX
Kailera Therapeutics
Galera Therapeutics
Kailera Therapeutics is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker GRTX. Primary therapeutic focus areas include SBRT, Covid19, Head and Neck Cancer, Oral Mucositis, Esophagitis.
Waltham, Massachusetts, United States HQ
2024 Founded
153 Employees
Public company Type
GRTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Waltham, Massachusetts, United States
- Founded
- 2024
- Employees
- 153
- Programs
- 17
- Drugs
- 7
- Patents
- 23
Drug GC4711
Phase 2 · small molecule · SBRT
Drug GC4711 for SBRT is a Phase 2 program (small_molecule) at Galera Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code GTI-4711-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Galera Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- SBRT
- Status
- terminated
- Trials
- 1